Kamada (NASDAQ:KMDA) Cut to Buy at StockNews.com

StockNews.com lowered shares of Kamada (NASDAQ:KMDA) from a strong-buy rating to a buy rating in a report published on Tuesday morning.

Several other equities research analysts have also commented on the company. Benchmark assumed coverage on Kamada in a research note on Friday, March 21st. They set a “buy” rating and a $15.00 price target on the stock. HC Wainwright reiterated a “buy” rating and set a $11.00 target price on shares of Kamada in a research report on Thursday, March 6th.

Kamada Trading Down 1.0 %

KMDA stock opened at $6.83 on Tuesday. The company’s 50-day moving average price is $7.18 and its 200 day moving average price is $6.29. Kamada has a 52 week low of $4.74 and a 52 week high of $9.16. The company has a market cap of $392.59 million, a P/E ratio of 24.39, a P/E/G ratio of 0.97 and a beta of 0.97.

Kamada Dividend Announcement

The firm also recently declared a — dividend, which will be paid on Monday, April 7th. Stockholders of record on Monday, March 17th will be given a $0.20 dividend. The ex-dividend date of this dividend is Monday, March 17th.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. NewEdge Advisors LLC grew its holdings in Kamada by 54.2% during the 4th quarter. NewEdge Advisors LLC now owns 23,496 shares of the biotechnology company’s stock valued at $143,000 after buying an additional 8,260 shares during the last quarter. Aristides Capital LLC boosted its stake in shares of Kamada by 12.1% during the fourth quarter. Aristides Capital LLC now owns 63,485 shares of the biotechnology company’s stock valued at $387,000 after acquiring an additional 6,850 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Kamada by 5.6% during the fourth quarter. Geode Capital Management LLC now owns 29,289 shares of the biotechnology company’s stock valued at $178,000 after acquiring an additional 1,549 shares during the last quarter. JPMorgan Chase & Co. purchased a new stake in Kamada during the 4th quarter worth about $67,000. Finally, Public Employees Retirement System of Ohio acquired a new position in Kamada in the 3rd quarter valued at about $77,000. 20.38% of the stock is currently owned by institutional investors and hedge funds.

About Kamada

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.